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Pharmacoeconomic impact of a patient-centric oncology service model
Kasey Rubin, PharmD; Samuel Jacobson PharmD, BCOP; Shannon Buxell, PharmD
Background
Objectives
Discussion
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References
•Primary outcomes
• Number of prescriptions filled by Credena specialty 
pharmacy
• Estimated revenue generated by pharmacists based 
on prescription quantity
•Secondary outcomes
•Patient reported pain scales (Numerical 1-10)
•Patient reported nausea scores (MOSES scale)
•Number of I-vents completed by pharmacists
Results
Number of Prescriptions
•Pharmacists utilize the home specialty site (Credena-
Halsey) instead of sending the prescription out of 
network
•Trend of prescriptions correlates appropriately to the 
increase in patients being seen at Providence Cancer 
Institute 
• In early months, pharmacists could have been under 
utilized as service line developed
•Examination of data outside timeline continues to show 
increase in prescriptions filled in house
Revenue
•Credena Health can fill prescriptions for all Providence 
Health Plans, a majority of Medicare Part D plans and 
Oregon Medicaid plans
•Medication agreements negotiated into action the start 
of 2019
•Revenue calculated between both sites are based off 
dispensing fees and reimbursement from insurance
Clinical Outcomes
•The pharmacist is ensuring that prescriptions are 
successfully received and are getting to the patients.
•Documentation regarding clinical outcomes were not 
clearly defined prior to the study, therefore found a lack 
of interventions
•Pharmacists reviewed supportive care, completed 
medication reconciliations, provided information on drug-
drug interactions, coordinated lab checks, adjusted doses 
based on medications, labs and diagnoses.
Data Limitations
•Retrospective study with manual data collection 
illustrating a short time frame
•Due to 340B pricing and differences in insurance 
reimbursement per person, revenue is not patient 
specific
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Health & Services
•Ambulatory oncology pharmacy is an expanding 
discipline of pharmacy with over 20 newly approved oral 
chemotherapy agents since 2017.1
•Clinical pharmacists are being integrated into health care 
teams across the country to serve as the medication 
experts for this specific subset of patients. 
•While current research in this field exists, the impact 
remains unclear due to the difficulty in quantifying 
metrics and interventions made by pharmacists. 
•Providence Health and Services employs a novel practice 
model, leveraging an embedded specialty pharmacy 
called Credena Health. 
•Credena Health is licensed in 49 states, however due to 
limited distribution networks and regional contracting 
not all patients can utilize as a specialty pharmacy. 
•For patient convenience, Credena Health facilities 
include a central distribution center, an oncology 
satellite, as well as concierge services available at other 
sites.
•Providence Cancer Institute cares for a diverse patient 
population. In this environment the pharmacist is a 
critical member of the interdisciplinary team
•In March of 2018 clinical pharmacists were embedded 
into the outpatient oncology clinics, removed from the 
dispensing role 
•The impact has not been formally evaluated 
•Goals include:
•Quantify the pharmacoeconomic benefit of  
embedded specialty pharmacy services
• Inform other facilities on processes to implement 
such services
•Analyze the pharmacist’s clinical impact by examining 
patient-centric factors
Purpose
• Evaluate the pharmacoeconomic impact of a pharmacist 
in an ambulatory oncology practice model
Methods
•Study design
•Retrospective
•Pre-Post
•Pre-intervention: March, 2017 – February, 2018
•Post-intervention: March, 2018 – March, 2019
•Inclusion criteria
•>18 years old
•Have had a visit to the ambulatory oncology clinic 
within the designated timeframe 
•Exclusion criteria
•Patients who were/are incarcerated
•Patients who were/are in mental institutions 
•Patients who were/are pregnant
•Patients with cognitive disability present
•Addition of pharmacists to the ambulatory care team has 
increased continuity of care for patients, increased 
revenue and prescription capture rate through Credena 
specialty pharmacy 
•Create revenue report to allow for number of oral 
antineoplastic prescriptions being filled by Credena Health, 
specifically by Providence physicians
•Generate report that calculates revenue generated by oral 
antineoplastic prescriptions
•Determine standardization between the sites and clear 
documentation of number of pharmacist interventions (I-
vents)
•Reconcile changes in medication regimens as direct result 
of pharmacist inclusion
Results
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